Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits
Go back to Independent Cleveland Clinic Review Finds No Clinically Significant Cardiotoxicity with Moleculin's Annamycin in R/R AML Patients Dosed Beyond Conventional Anthracycline Limits| METABASIS THERAPEUT (NASDAQ: MBRX) | Delayed: 2.64 -0.06 (2.22%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $2.70 | 52 Week High | $9.58 | |||
| Open | $2.69 | 52 Week Low | $2.34 | |||
| Day High | $2.79 | P/E | N/A | |||
| Day Low | $2.60 | EPS | $-0.34 | |||
| Volume | 199,609 | |||||
